Close Menu

NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2019 Q1 net loss rose about two percent year over year, as the firm nears the launch of its non-invasive lung cancer detection test, DetermaVu.

The liquid biopsy firm's net loss for the three months ended March 31, 2019 was $3.9 million, or $.08 per share, compared to a net loss of $3.8 million, or $.12 per share, in the same quarter last year, slightly beating the consensus Wall Street estimate of a loss of $.09 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.